Ting Song1, Gaobo Chai2, Yubo Liu2, Xiaoyan Yu2, Ziqian Wang1, Zhichao Zhang1. 1. State Key Laboratory of Fine Chemicals, School of Chemistry, Dalian University of Technology, Dalian, China. 2. School of Life Science and Technology, Dalian University of Technology, Dalian, China.
Abstract
BACKGROUND AND PURPOSE: Although the ongoing clinical trials of ABT-263 and ABT-199 in chronic lymphocytic leukaemia (CLL) have indicated that BH3 mimetics hold considerable promise, understanding the mechanism of CLL resistance to BH3 mimetics remains a challenge. EXPERIMENTAL APPROACH: The LD50 values of ABT-737, ABT-263 and ABT-199 in a number of primary CLL cells from 40 patients, were determined. The levels of Bcl-2 family proteins, including phosphorylated Bcl-2 (pBcl-2) and their interactions were measured by immunoblotting and co-immunoprecipitation. In vitro binding assays were performed by isothermal titration calorimetry and ELISA. BH3 profiling in isolated mitochondria was analysed. KEY RESULTS: The ratio of (Mcl-1 + pBcl-2) to Bcl-2 expression provided the most significant predictive marker for the cytotoxic potential of ABT-737, ABT-263 and ABT-199 in the panel of CLL samples. Mechanistically, pBcl-2 inhibited the effects of the ABT compounds on the displacement of Bax and Bim from Bcl-2, thereby suppressing mitochondrial apoptosis. The ABT compounds exhibited 100-300-fold lower binding affinity to the glutamic acid, phosphomimetic, mutant of Bcl-2 (T69E, S70E and S87E; EEE-Bcl-2). BH3 peptides exhibited different rank orders of binding affinities to full-length WT-Bcl-2 and full-length EEE-Bcl-2. CONCLUSIONS AND IMPLICATIONS: Our study suggested that a structural alteration in the BH3-binding groove was induced by phosphorylation of Bcl-2. Our data also provided a framework to overcome resistance of CLL cells to the ABT compounds by combining pBcl-2 kinase inhibitors with the ABT compounds.
BACKGROUND AND PURPOSE: Although the ongoing clinical trials of ABT-263 and ABT-199 in chronic lymphocytic leukaemia (CLL) have indicated that BH3 mimetics hold considerable promise, understanding the mechanism of CLL resistance to BH3 mimetics remains a challenge. EXPERIMENTAL APPROACH: The LD50 values of ABT-737, ABT-263 and ABT-199 in a number of primary CLL cells from 40 patients, were determined. The levels of Bcl-2 family proteins, including phosphorylated Bcl-2 (pBcl-2) and their interactions were measured by immunoblotting and co-immunoprecipitation. In vitro binding assays were performed by isothermal titration calorimetry and ELISA. BH3 profiling in isolated mitochondria was analysed. KEY RESULTS: The ratio of (Mcl-1 + pBcl-2) to Bcl-2 expression provided the most significant predictive marker for the cytotoxic potential of ABT-737, ABT-263 and ABT-199 in the panel of CLL samples. Mechanistically, pBcl-2 inhibited the effects of the ABT compounds on the displacement of Bax and Bim from Bcl-2, thereby suppressing mitochondrial apoptosis. The ABT compounds exhibited 100-300-fold lower binding affinity to the glutamic acid, phosphomimetic, mutant of Bcl-2 (T69E, S70E and S87E; EEE-Bcl-2). BH3 peptides exhibited different rank orders of binding affinities to full-length WT-Bcl-2 and full-length EEE-Bcl-2. CONCLUSIONS AND IMPLICATIONS: Our study suggested that a structural alteration in the BH3-binding groove was induced by phosphorylation of Bcl-2. Our data also provided a framework to overcome resistance of CLL cells to the ABT compounds by combining pBcl-2 kinase inhibitors with the ABT compounds.
Authors: K Maundrell; B Antonsson; E Magnenat; M Camps; M Muda; C Chabert; C Gillieron; U Boschert; E Vial-Knecht; J C Martinou; S Arkinstall Journal: J Biol Chem Date: 1997-10-03 Impact factor: 5.157
Authors: Andrew W Roberts; John F Seymour; Jennifer R Brown; William G Wierda; Thomas J Kipps; Seong Lin Khaw; Dennis A Carney; Simon Z He; David C S Huang; Hao Xiong; Yue Cui; Todd A Busman; Evelyn M McKeegan; Andrew P Krivoshik; Sari H Enschede; Rod Humerickhouse Journal: J Clin Oncol Date: 2011-12-19 Impact factor: 44.544
Authors: Joel D Leverson; Deepak Sampath; Andrew J Souers; Saul H Rosenberg; Wayne J Fairbrother; Martine Amiot; Marina Konopleva; Anthony Letai Journal: Cancer Discov Date: 2017-11-16 Impact factor: 39.397
Authors: Angel Y F Kam; Sadhna O Piryani; Chang-Lung Lee; David A Rizzieri; Neil L Spector; Stefanie Sarantopoulos; Phuong L Doan Journal: Mol Cancer Res Date: 2021-01-29 Impact factor: 6.333
Authors: Ji Liang; Ruixiu Cao; Xiongjun Wang; Yajuan Zhang; Pan Wang; Hong Gao; Chen Li; Fan Yang; Rong Zeng; Ping Wei; Dawei Li; Wenfeng Li; Weiwei Yang Journal: Cell Res Date: 2016-12-30 Impact factor: 25.617